Dapivirine
Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV. It was developed by the pharmaceutical company Gilead Sciences and was approved for use in the United States in 2012. Dapivirine is available in a once-daily oral tablet form and is often used in combination with other antiretroviral drugs to manage HIV infection.
The primary mechanism of action of dapivirine is to inhibit the reverse transcriptase enzyme, which is crucial
Dapivirine is particularly notable for its use in the PrEP (Pre-Exposure Prophylaxis) regimen, where it is combined
In addition to its use in HIV treatment and prevention, dapivirine has also been studied for its
Dapivirine is generally well-tolerated, with common side effects including headache, nausea, and diarrhea. Serious side effects